Evaluation on effect of feiji recipe on quality of life of patients with non-small cell lung cancer by adopting international questionnaire of QOL.
- Author:
Jie YOU
1
;
Zhi-Ming SHI
;
Bao-Hui HAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Health Status Indicators; Humans; International Cooperation; Lung Neoplasms; drug therapy; Male; Medicine, Chinese Traditional; Middle Aged; Phytotherapy; Quality of Life; Surveys and Questionnaires
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(1):33-37
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of Feiji Recipe (FJR) on quality of life (QOL) of patients with non-small cell lung cancer (NSCLC).
METHODSOne hundred and two patients with NSCLC were randomly assigned into 2 groups. The 61 patients in the combined treated group were given FJR and chemotherapy and the 41 patients in the control group were treated with chemotherapy alone. They were observed for two treatment courses with QOL estimated by EORTC QLQ-C43 questionnaire and FACT-L questionnaire, the two international questionnaires as the tools for measurement, and referred to the traditional evaluating indexes of clinical efficiency.
RESULTSQOL in the combined treated group was improved after treatment with the improvement of scores in all domains, including functional and symptom sub-domain, while it in the control group deprived significantly, showing significant difference between the two groups (P < 0.05). Similar results were also shown in the evaluation of physical performance by Eastern Cooperative Oncology Group (ECOG) and Karnovfsky performance scoring. The gastrointestinal reaction and myelo-suppression were slighter in the combined treated group than those in the control group (P < 0.05), and no significant difference was shown between the response rate of the two groups (P > 0.05).
CONCLUSIONFJR can improve QOL of patients with NSCLC, reduce the adverse reaction of chemotherapy, and improve patients' physical performance.
